A phase 2, randomized study of nivolumab or nivolumab plus BMS-986205 with or without intravesical bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer: CheckMate 9UT

J.A. Witjes, J. Gschwend,J. Palou, M. Meng, S. Chang, N. Shore,B. Konety,G. Steinberg,H. Nishiyama,J.A. Taylor,A. Elegbe,A. Lambert, L. Zhu, Y. Ishii, T. Maeda, B. Raybold, G. Grossfeld,B. Fischer, M. Rutstein,N. Hahn

European Urology Supplements（2019）

Cited 4|Views49

No score

Key words

Bacillus Calmette-Guerin

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined